Vaccination with plasmid DNA encoding TSA/LmSTI1 Leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice

Infection and Immunity

Volumn 70, Issue 6, 2002, Pages 2828-2836

  Campos Neto, A ^a   Webb, J R ^a   Greeson, K ^a   Coler, R N ^a   Skeiky, Y A W ^a   Reed, S G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 12; LSMTI1 PROTEIN; PLASMID DNA; RECOMBINANT ANTIGEN; TSA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL DISEASE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DNA DETERMINATION; GENE CONSTRUCT; GENE FUSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION SENSITIVITY; LEISHMANIA MAJOR; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARASITOSIS; PHENOTYPE; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TH1 CELL; VACCINE PRODUCTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; DNA, PROTOZOAN; HEAT-SHOCK PROTEINS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEROXIDASES; PLASMIDS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINATION; VACCINES, DNA;

EID: 0036263309     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.6.2828-2836.2002     Document Type: Article

References (57)

1. Mediterranean leishmaniasis in HIV-infected patients: Epidemiological, clinical, and diagnostic features of 22 cases
2. DNA vaccines: Technology and application as anti-parasite and anti-microbial agents
3. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
4. CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis
5. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
6. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobaeterium tuberculosis
7. Leishmania major infection in mice primes for specific major histocompatibility complex class I-restricted CD8+ cytotoxic T cell responses
8. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis
9. Leishmania, Trypanosoma and monoxenous trypanosomatids as emerging opportunistic agents
10. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
11. DNA vaccines
12. Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis
13. Cutting edge: Mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12
14. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection
15. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters
16. Nitric oxide: Cytokine-regulation of nitric oxide in host resistance to intracellular pathogens
17. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity, to mice infected with Leishmania major
18. DNA vaccines: A key for inducing long-term cellular immunity
19. Therapy of murine cutaneous leishmaniasis by DNA vaccination
20. A Toll-like receptor recognizes bacterial DNA
21. Mechanisms of macrophage stimulation through CD8: Macrophage CD8α and CD8β induce nitric oxide production and associated killing of the parasite Leishmania major
22. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages
23. Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production
24. Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice
25. The inhibition of arginase by N(omega)-hydroxy-1-arginine controls the growth of Leishmania inside macrophages
26. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
27. Enhancing vaccines with immune stimulatory CpG DNA
28. The role of CpG dinucleotides in DNA vaccines
29. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells
30. Progress in the development of an HIV-1 vaccine
31. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages
32. Therapy of tuberculosis in mice by DNA vaccination
33. Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC
34. Epidemiology of the leishmaniases
35. Immunology of DNA vaccines: CpG motifs and antigen presentation
36. + antigen-specific T cells
37. Cytotoxic T lymphocytes in resistance to tuberculosis
38. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library
39. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge
40. Role of T cell subsets during the recall of immunologic memory to Leishmania major
41. Kala-azar as an AIDS-related opportunistic infection
42. Macrophage microbicidal mechanisms in vivo: Reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani
43. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major
44. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
45. DNA vaccination: Antigen presentation and the induction of immunity
46. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection
47. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
48. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major
49. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge
50. Cutting edge: Role of toll-like receptor 9 in cpg DNA-induced activation of human cells
51. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms
52. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis
53. DNA vaccination strategies against infectious diseases
54. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
55. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
56. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
57. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis